Vaccibody As Valuation
| VACCDelisted Stock | USD 2.23 0.04 1.83% |
Based on Macroaxis valuation methodology, the company appears to be overvalued. Vaccibody As has a current Real Value of $1.9 per share. The regular price of the company is $2.23. Our model measures the value of Vaccibody As from inspecting the company fundamentals such as Current Valuation of 32.03 M, return on equity of -0.23, and Shares Owned By Insiders of 3.45 % as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Vaccibody's price fluctuation is very steady at this time. Calculation of the real value of Vaccibody As is based on 3 months time horizon. Increasing Vaccibody's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Vaccibody is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Vaccibody Stock. However, Vaccibody's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.23 | Real 1.9 | Hype 2.23 |
The real value of Vaccibody Stock, also known as its intrinsic value, is the underlying worth of Vaccibody As Company, which is reflected in its stock price. It is based on Vaccibody's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Vaccibody's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Vaccibody As helps investors to forecast how Vaccibody stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Vaccibody more accurately as focusing exclusively on Vaccibody's fundamentals will not take into account other important factors: Vaccibody Total Value Analysis
Vaccibody As is at this time forecasted to have valuation of 32.03 M with market capitalization of 192.73 M, debt of 8.77 M, and cash on hands of 192.33 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Vaccibody fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
32.03 M | 192.73 M | 8.77 M | 192.33 M |
Vaccibody Investor Information
About 50.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 0.36. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Vaccibody As recorded a loss per share of 1.59. The entity had not issued any dividends in recent years. Based on the key measurements obtained from Vaccibody's financial statements, Vaccibody As is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Vaccibody Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Vaccibody has an asset utilization ratio of 16.54 percent. This indicates that the Company is making $0.17 for each dollar of assets. An increasing asset utilization means that Vaccibody As is more efficient with each dollar of assets it utilizes for everyday operations.Vaccibody Ownership Allocation
Vaccibody As shows a total of 38.55 Million outstanding shares. 30% of Vaccibody As outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Vaccibody Profitability Analysis
The company reported the previous year's revenue of 44.7 M. Net Income was 5.32 M with profit before overhead, payroll, taxes, and interest of 44.7 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Vaccibody's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Vaccibody and how it compares across the competition.
About Vaccibody Valuation
The delisted stock valuation mechanism determines Vaccibody's current worth on a weekly basis. Our valuation model uses a comparative analysis of Vaccibody. We calculate exposure to Vaccibody's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Vaccibody's related companies.Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. Vaccitech Plc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.
8 Steps to conduct Vaccibody's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Vaccibody's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Vaccibody's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Vaccibody's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Vaccibody's revenue streams: Identify Vaccibody's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Vaccibody's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Vaccibody's growth potential: Evaluate Vaccibody's management, business model, and growth potential.
- Determine Vaccibody's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Vaccibody's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |